FibroGen, Inc. Announces Full Exercise of Greenshoe Option

SAN FRANCISCO--()--FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price of $18.00 per share, less the underwriting discount. With this exercise, the initial public offering totals 9,315,000 shares of common stock of FibroGen, representing gross proceeds of approximately $167.7 million, prior to deducting the underwriting discount and estimated offering expenses.

The Company’s common stock started trading on the NASDAQ Global Select Market on November 14, 2014. The offering is expected to close on November 19, 2014, subject to customary closing conditions.

Goldman, Sachs & Co., Citigroup Global Markets Inc., and Leerink Partners LLC are acting as joint book-running managers of the offering. RBC Capital Markets, LLC, Stifel, Nicolaus & Company, Incorporated, and William Blair & Company, L.L.C. are acting as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on November 13, 2014. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a written prospectus. A copy of the final prospectus relating to these securities, when available, may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, via telephone at (866) 471-2526 or by email to prospectus-ny@ny.email.gs.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at (800) 831-9146 or by email to prospectus@citi.com; or Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, via telephone at (800) 808-7525, ext. 6142 or by email to syndicate@leerink.com.

About FibroGen

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia in chronic kidney disease patients who are dialysis-dependent, including hemodialysis and peritoneal dialysis, and not dialysis-dependent.

Contacts

FibroGen, Inc.
Greg Mann, 415-978-1433
gmann@fibrogen.com

FibroGen, Inc.